PharmiWeb
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Prov
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...
4 days ago